Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
KUALA LUMPUR, 14 JULY 2022 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) and US-based foodtech company The Live Green Co. signed a Collaboration Agreement today to explore the use of plant ingredients and technology to replace animal, synthetic and ultra-processed ingredients, to meet consumer demand for more sustainable wellness foods and pharmaceuticals.
● Duopharma Biotech Berhad’s 21st AGM reaffirms the Group’s commitment to maintaining its leading position as an innovative pharmaceutical company in Malaysia and a global leader in the halal sector
● Intensified focus on ESG has made the Group a preferred employer, trusted partner, attractive investment and an increasingly strong brand
Kuala Lumpur, June 15, 2022 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company“) hosted the Third (3rd) Halal Pharmaceuticals Symposium 2022 today, as part of The Company’s continuing quest to spearhead efforts to capture the global halal pharmaceuticals market by facilitating the sharing of best practices, achievements and international collaborations to resolve challenges, advance global standards and jointly shape the industry.
● 1Q 2022 PBT increased by 15% to RM26.65 million compared to previous corresponding quarter
● Revenue gained 12% to RM185.94 million year-on-year
● Improving Malaysian economy, recovery in domestic demand bode well for Duopharma Biotech’s prospects